In a retrospective cohort study, TACE combined with lenvatinib and a programmed cell death 1 (PD-1) inhibitor significantly improved survival and tumor response compared to TACE combined with lenvatinib in advanced HCC patients, especially those with extrahepatic metastasis or multiple tumors (13). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.